ijms-logo

Journal Browser

Journal Browser

Gene and Cell-Based Cancer Therapies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 9683

Special Issue Editors


E-Mail
Guest Editor
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Interests: cancer; fibrosis; stem/progenitor cell biology; gene therapy; cell therapy

E-Mail
Guest Editor
Morehouse school of Medicine, Atlanta, GA, USA
Interests: breast and ovarian cancer; complementary and alternative medicine for reproductive health

Special Issue Information

Dear Colleagues,

Since the discovery of recombinant DNA technology and our increasing ability to transfer gene(s) from organism to organism, the idea of gene therapy to cure inherited human diseases took shape. As the structures and biology of the common bacteria and viruses infecting humans became known, they were engineered to carry therapeutic genes of interest and deliver them in desired tissues/organs. After some initial hurdles, gene therapy has come a long way, as evidenced by the growing number of clinical trials and approvals by the FDA and the EMA for clinical use. In contrast, cancer gene therapy is in the works with modest success, which is primarily due to heterogeneity in the disease process. Gene therapy can be a game changer for the treatment of cancers, mainly childhood cancers in offering long-term cures. CAR-T cell therapy, which was recently approved for human use for certain blood cancers, is an extension of gene therapy involving genetic modification of patient’s T-cells ex vivo to efficiently recognize and kill cancer cells when given back to the patient. There is room for improvement, and the race is on to extend its scope to solid tumors. In this Special Issue, we will celebrate your original research or review articles enriching the promise of gene- and cell-based therapies in cancer. IJMS MDPI is a peer-reviewed open-access journal with a high impact factor representing a great way to reach out to a broad readership who can also immensely benefit from your work. Therefore, we are encouraging you to submit your valuable observations, findings and vision to IJMS. Thank you.

The topics of interest for our Special Issue include but are not limited to:

  1. Technological advancements in vector design for cancer gene therapy;
  2. Application of gene and cell therapy in different cancer types;
  3. Use of gene editing technologies in cancer treatments;
  4. Induced pluripotent stem-cell-based cancer therapies;
  5. Tumor-specific gene targeting methods;
  6. Immunomodulation in cancer treatments;
  7. Cancer cell reprogramming by gene transfers 
Dr. Diptiman Chanda
Dr. Indrajit Chowdhury
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • oncology
  • metastasis
  • stem cells
  • gene therapy
  • cell therapy
  • immunotherapy
  • CRISPR-cas9
  • gene editing
  • induced pluripotent stem cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 1547 KiB  
Review
Targeting Cancer with CRISPR/Cas9-Based Therapy
by Katarzyna Balon, Adam Sheriff, Joanna Jacków and Łukasz Łaczmański
Int. J. Mol. Sci. 2022, 23(1), 573; https://doi.org/10.3390/ijms23010573 - 5 Jan 2022
Cited by 26 | Viewed by 8896
Abstract
Cancer is a devastating condition characterised by the uncontrolled division of cells with many forms remaining resistant to current treatment. A hallmark of cancer is the gradual accumulation of somatic mutations which drive tumorigenesis in cancerous cells, creating a mutation landscape distinctive to [...] Read more.
Cancer is a devastating condition characterised by the uncontrolled division of cells with many forms remaining resistant to current treatment. A hallmark of cancer is the gradual accumulation of somatic mutations which drive tumorigenesis in cancerous cells, creating a mutation landscape distinctive to a cancer type, an individual patient or even a single tumour lesion. Gene editing with CRISPR/Cas9-based tools now enables the precise and permanent targeting of mutations and offers an opportunity to harness this technology to target oncogenic mutations. However, the development of safe and effective gene editing therapies for cancer relies on careful design to spare normal cells and avoid introducing other mutations. This article aims to describe recent advancements in cancer-selective treatments based on the CRISPR/Cas9 system, especially focusing on strategies for targeted delivery of the CRISPR/Cas9 machinery to affected cells, controlling Cas9 expression in tissues of interest and disrupting cancer-specific genes to result in selective death of malignant cells. Full article
(This article belongs to the Special Issue Gene and Cell-Based Cancer Therapies)
Show Figures

Figure 1

Back to TopTop